About this trial
Unblinded, controlled, non-randomized, mechanistic study to determine whether physiological mechanisms underlying PVC are sensitive to adenosine. One hundred subjects undergoing clinically-indicated, standard-of-care cardiac electrophysiology study (EPS) procedure for PVCs will receive adenosine and/or verapamil to learn if their arrhythmias are inducible similarly to sustained ventricular tachycardia.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Diagnosis of premature ventricular contractions (PVCs)
Scheduled to undergo an electrophysiology study with the intention of performing cardiac ablation for the treatment of PVCs
Male or female between the ages of 18 and 70 years
Capable of giving informed consent
Disqualifiers
Any structural heart disease
Coronary artery disease (≥ 70% stenosis)
Current treatment with anti-arrhythmic drugs
Pregnant
Trial design
Single group
Treatments tested in this trial
Adenosine
DrugAdenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
Treatment groups
Trial outcomes
Primary outcomes
Effects of Adenosine on premature ventricular contractions (PVCs) as measured by EKG;
The metrics that will be collected will be: * Baseline frequency of premature ventricular contractions (PVCs) * Frequency of premature ventricular contractions (PVCs) during adenosine administration
Effects of verapamil on premature ventricular contractions (PVCs) as measured by EKGs.
The metrics that will be collected will be: * Baseline frequency of premature ventricular contractions (PVCs) * Frequency of premature ventricular contractions (PVCs) during verapamil administration
Sponsors and contacts
Click on the lead sponsor to view all of their trials.